Zhong Zhong

Title: Innovations by Zhong Zhong in Cardiotoxicity Screening

Introduction

Zhong Zhong is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of cardiotoxicity screening, holding 2 patents that focus on innovative methods and assays. His work is particularly relevant in the context of drug development and safety assessment.

Latest Patents

Zhong's latest patents include a "Fluorescence polarization hERG assay," which discloses assays, methods, and kits for screening test compounds for their capability to induce cardiotoxicity in a subject. This patent specifically addresses whether a test compound can prolong the Q-T interval as measured by an electrocardiogram in humans. The assays utilize the binding interaction between novel fluorescent tracers and the hERG K-channel, assessing the influence of test compounds on this interaction.

Another notable patent is the "Method for using division arrested cells in screening assays." This invention employs division arrested cells to determine the effect of substances on the cells. These cells are particularly useful in drug screening assays, signal transduction assays, and large-scale, high-throughput assays.

Career Highlights

Zhong Zhong is currently associated with Life Technologies Corporation, where he continues to innovate in the field of biotechnology. His work has implications for improving drug safety and efficacy, making significant strides in the pharmaceutical industry.

Collaborations

Zhong collaborates with notable colleagues, including Thomas Livelli and Mohammed Saleh Shekhani. Their combined expertise enhances the research and development efforts at Life Technologies Corporation.

Conclusion

Zhong Zhong's contributions to cardiotoxicity screening through his innovative patents demonstrate his commitment to advancing drug safety. His work is vital for the future of pharmaceutical research and development.